Traditional vaccine development methods require significant time and expense to reach final products.These methods also lack the flexibility to screen and test multiple product constructs in the clinic. Finally, traditional methods produce vaccines which require cold chain infrastructure.
To advance transformational vaccine development and delivery platforms to accelerate development and delivery of low-cost vaccines against infectious diseases that disproportionately impact people in developing countries.
Biotech company focused on utilizing long-chain mRNA to instruct the human body to produce its own proteins for immunotherapy or prophylactic vaccines.
Foundation focus: Leverage the mRNA platform to significantly reduce timelines and manufacturing cost involved in developing thermostable vaccines against the foundation’s target diseases.
Series B preferred equity
Date: February 2015
Co-Investors: dievini Hopp Biotech
Associated funding: multiple current and future grants to fund specific disease research and development programs